Cargando…

Monotherapy in patients with type 2 diabetes mellitus

In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhee, Sang Youl, Kim, Hyun Jin, Ko, Seung-Hyun, Hur, Kyu Yeon, Kim, Nan-Hee, Moon, Min Kyong, Park, Seok-O, Lee, Byung-Wan, Choi, Kyung Mook, Kim, Jin Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668404/
https://www.ncbi.nlm.nih.gov/pubmed/29057643
http://dx.doi.org/10.3904/kjim.2017.312
_version_ 1783275668485701632
author Rhee, Sang Youl
Kim, Hyun Jin
Ko, Seung-Hyun
Hur, Kyu Yeon
Kim, Nan-Hee
Moon, Min Kyong
Park, Seok-O
Lee, Byung-Wan
Choi, Kyung Mook
Kim, Jin Hwa
author_facet Rhee, Sang Youl
Kim, Hyun Jin
Ko, Seung-Hyun
Hur, Kyu Yeon
Kim, Nan-Hee
Moon, Min Kyong
Park, Seok-O
Lee, Byung-Wan
Choi, Kyung Mook
Kim, Jin Hwa
author_sort Rhee, Sang Youl
collection PubMed
description In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly.
format Online
Article
Text
id pubmed-5668404
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-56684042017-11-13 Monotherapy in patients with type 2 diabetes mellitus Rhee, Sang Youl Kim, Hyun Jin Ko, Seung-Hyun Hur, Kyu Yeon Kim, Nan-Hee Moon, Min Kyong Park, Seok-O Lee, Byung-Wan Choi, Kyung Mook Kim, Jin Hwa Korean J Intern Med Review In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly. The Korean Association of Internal Medicine 2017-11 2017-10-23 /pmc/articles/PMC5668404/ /pubmed/29057643 http://dx.doi.org/10.3904/kjim.2017.312 Text en Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Rhee, Sang Youl
Kim, Hyun Jin
Ko, Seung-Hyun
Hur, Kyu Yeon
Kim, Nan-Hee
Moon, Min Kyong
Park, Seok-O
Lee, Byung-Wan
Choi, Kyung Mook
Kim, Jin Hwa
Monotherapy in patients with type 2 diabetes mellitus
title Monotherapy in patients with type 2 diabetes mellitus
title_full Monotherapy in patients with type 2 diabetes mellitus
title_fullStr Monotherapy in patients with type 2 diabetes mellitus
title_full_unstemmed Monotherapy in patients with type 2 diabetes mellitus
title_short Monotherapy in patients with type 2 diabetes mellitus
title_sort monotherapy in patients with type 2 diabetes mellitus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668404/
https://www.ncbi.nlm.nih.gov/pubmed/29057643
http://dx.doi.org/10.3904/kjim.2017.312
work_keys_str_mv AT rheesangyoul monotherapyinpatientswithtype2diabetesmellitus
AT kimhyunjin monotherapyinpatientswithtype2diabetesmellitus
AT koseunghyun monotherapyinpatientswithtype2diabetesmellitus
AT hurkyuyeon monotherapyinpatientswithtype2diabetesmellitus
AT kimnanhee monotherapyinpatientswithtype2diabetesmellitus
AT moonminkyong monotherapyinpatientswithtype2diabetesmellitus
AT parkseoko monotherapyinpatientswithtype2diabetesmellitus
AT leebyungwan monotherapyinpatientswithtype2diabetesmellitus
AT choikyungmook monotherapyinpatientswithtype2diabetesmellitus
AT kimjinhwa monotherapyinpatientswithtype2diabetesmellitus
AT monotherapyinpatientswithtype2diabetesmellitus